

CLAIMS

1. A pharmaceutical composition comprising the hemitartrate salt of a compound represented by the following structural formula:



and a pharmaceutically acceptable carrier or diluent, wherein at least 70 % by weight of the salt is the single crystalline form Form A.

2. A pharmaceutical composition comprising the hemitartrate salt of a compound represented by the following structural formula:



and a pharmaceutically acceptable carrier or diluent, wherein at least 70% by weight of the salt is in a single crystalline form, and wherein the single crystalline form is characterized by:

(a) at least one major x-ray powder diffraction peak at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°;


(b) at least two major x-ray powder diffraction peaks at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°;

(c) at least three major x-ray powder diffraction peaks at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°;

(d) at least four major x-ray powder diffraction peaks at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°; or


(e) major x-ray powder diffraction peaks at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°.

3. A pharmaceutical composition comprising the hemitartrate salt of a compound represented by the following structural formula:



and a pharmaceutically acceptable carrier or diluent, wherein at least 70% by weight of the salt is in a single crystalline form, and wherein the single crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of 5.1°, 6.6°, 10.7°, 11.0°, 13.3°, 15.1°, 15.9°, 16.5°, 17.6°, 18.6°, 18.7°, 19.0°, 20.2°, 21.7° and 23.5°.

4. A pharmaceutical composition comprising the hemitartrate salt of a compound represented by the following structural formula:



and a pharmaceutically acceptable carrier or diluent, wherein at least 70% by weight of the salt is in a single crystalline form, and wherein the single crystalline form is characterized by x-ray powder diffraction pattern of FIG. 1.

5. The pharmaceutical composition of any one of Claims 1 to 4, wherein at least 99% by weight of the salt is in a single crystalline form.

6. A pharmaceutical composition comprising:
- a hemitartrate salt as defined in any one of Claims 1 to 5;
- at least one water-soluble filler;
- at least one water-insoluble filler;
- at least one binder; and
- at least one lubricant.

7. The pharmaceutical composition of Claim 6, wherein:
(a) the water-soluble filler is selected from the group consisting of anhydrous lactose, lactose monohydrate, mannitol, sodium chloride, powdered sugar, sorbitol, sucrose, inositol and pregelatinized starch;
(b) the water-insoluble filler is selected from the group consisting of microcrystalline cellulose, calcium phosphate and starch;
(c) the binder is selected from the group consisting of pre-gelatinized starch, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, copolyvidone, gelatin, natural gums, starch paste, sucrose, corn syrup, polyethylene glycols and sodium alginate; or
(d) the lubricant is selected from the group consisting of hydrogenated vegetable oil, calcium stearate, and glyceryl behenate.

8. The pharmaceutical composition of Claim 6, wherein:
(a) the water-soluble filler is selected from the group consisting of anhydrous lactose, lactose monohydrate, mannitol, sodium chloride, powdered sugar, sorbitol, sucrose, inositol and pregelatinized starch;
(b) the water-insoluble filler is selected from the group consisting of microcrystalline cellulose, calcium phosphate and starch;
(c) the binder is selected from the group consisting of pre-gelatinized starch, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose,

polyvinyl pyrrolidone, copolyvidone, gelatin, natural gums, starch paste, sucrose, corn syrup, polyethylene glycols and sodium alginate; and

(d) the lubricant is selected from the group consisting of hydrogenated vegetable oil, calcium stearate, and glyceryl behenate.

9. The pharmaceutical composition of Claim 8, wherein the composition comprises:

(a) 26 wt% to 50 wt% of the water-soluble filler on a dry solids basis;

(b) 8 wt% to 32 wt%, 8 wt% to 24 wt% or 12 wt% to 20 wt% of the water-insoluble filler on a dry solids basis;

(c) 2 wt% to 6 wt% of the binder on a dry solids basis; or

(d) 0.1 wt% to 2 wt% of a lubricant on a dry solids basis.

10. The pharmaceutical composition of Claim 8, wherein the composition comprises 14 wt% to 18 wt% of the water-insoluble filler on a dry solids basis.

11. The pharmaceutical composition of Claim 8, wherein the composition comprises:

(a) 35 wt% to 40 wt% of the hemitartrate salt;

(b) 26 wt% to 50 wt% of the water-soluble filler;

(c) 8 wt% to 32 wt% of the water-insoluble filler;

(d) 2 wt% to 6 wt% of the binder; and

(e) 0.1 wt% to 2 wt% of the lubricant,

all on a dry solids basis.

12. The pharmaceutical composition of Claim 8, wherein:

(a) the water-soluble filler is lactose monohydrate;

(b) the water-insoluble filler is microcrystalline cellulose;

(c) the binder is hydroxypropyl methylcellulose; and

(d) the lubricant is glyceryl behenate.

13. The pharmaceutical composition of claim 12, wherein the composition comprises:

(a) 35 wt% to 40 wt% of the hemitartrate salt;

(b) 26 wt% to 50 wt% of the lactose monohydrate;

(c) 8 wt% to 32 wt% of the microcrystalline cellulose;

(d) 2 wt% to 6 wt% of the hydroxypropyl methylcellulose; and

(e) 0.1 wt% to 2 wt% of the glyceryl behenate,

all on a dry solids basis.

14. A hemitartrate salt as defined in any one of claims 1 to 5.

15. Use of a hemitartrate salt according to Claim 14 in the manufacture of a medicament for the treatment of Gaucher disease or Fabry disease in a subject.

16. Use of a hemitartrate salt according to Claim 14 in the manufacture of a medicament for inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof.

17. The use according to Claim 15 or 16, wherein the salt is administered at a twice daily dose of from 25 milligrams to 200 milligrams.

18. The use according to Claim 15 or 16, wherein the salt is administered at a twice daily dose of 50 milligrams.